Science

Selpercatinib in RET Fusion-Positive NSCLC by Oliver Gautschi et al.

Oliver Gautschi/emedevents.com

Mar 3, 2025, 15:56

Selpercatinib in RET Fusion-Positive NSCLC by Oliver Gautschi et al.

A paper by Oliver Gautschi et al. was published in the Journal of Clinical Oncology, titled:

“Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial”

Authors: Oliver Gautschi, Keunchil Park, Benjamin Solomon, Bente Frimodt-Moller, Alexander Drilon et al.

Selpercatinib, a selective and potent RET kinase inhibitor with CNS activity, has demonstrated strong and durable responses in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The LIBRETTO-001 trial, a phase I/II single-arm study, evaluated selpercatinib in 316 patients, including 69 who were treatment-naive and 247 who had previously received platinum-based chemotherapy.

Among pretreated patients, the objective response rate (ORR) was 62%, with a median duration of response (DoR) of 31.6 months and a median progression-free survival (PFS) of 26.2 months. In treatment-naive patients, the ORR was 83%, with a DoR of 20.3 months and a PFS of 22.0 months.

Median overall survival was 47.6 months for pretreated patients, while it was not reached in the treatment-naive group. At the three-year follow-up, 57% of pretreated and 66% of treatment-naive patients were still alive.

Among 26 patients with measurable central nervous system (CNS) metastases at baseline, the intracranial ORR was 85%, with a median CNS-DoR of 9.4 months and CNS-PFS of 11.0 months. In the full safety population of 796 patients, the median treatment duration was 36.1 months, and the safety profile remained consistent with prior reports.

These findings confirm that selpercatinib provides sustained efficacy, including intracranial benefits, in both previously treated and treatment-naive patients with RET fusion-positive NSCLC while maintaining a manageable safety profile.

Read more posts about NSCLC on oncodaily.com.

Alexander Drilon Benjamin Solomon Bente Frimodt-Moller cancer Keunchil Park non small cell lung cancer NSCLC Oliver Gautschi OncoDaily Oncology Selpercatinib

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma